# Process Systems and **Rigorous Parameter Estimation for Operations** Research **Model Validation in Oncological Systems** aboratory



Chenyu Wang<sup>1</sup>, John D. Martin<sup>2</sup>, Horacio Cabral<sup>2</sup>, Matthew D. Stuber<sup>1</sup>

# 2. Chemotherapy Adjunct Increases Nanocarrier Delivery<sup>[5]</sup>

• Confocal intravital microscopy images of 4T1 tumors treated with control (A), low-dose(B), or high-dose (C) chemotherapy adjunct one hour after co-injection of 70 kDa (13 nm,red) and500 kDa (32 nm, green)fluorescent dextrans.

• (D) Low-dose (orange squares) highly increase the effective permeability of the tumor vessels; • (E) Schematic of effective permeability: a measure of the rate that nanocarriers extravasate blood vessels.

• (F) Prediction of vessel wall pore size from the tumor model; • (G) The small pore size after high-dose treatment sterically hinders extravasation.

• (H) Prediction of interstitial hydraulic conductivity from the tumor model; • (I) Schematic of interstitial hydraulic conductivity: a measure of the rate that fluids traverse the extravascular space.

• Parameter Estimation Optimization Minimize the SSE between the average

concentration of the model and data over the whole time horizon;

Characterize the vascular normalization process after pretreatment chemotherapy adjunct;























• Lower bound and upper bound are derived from interval extensions using the standard error from experiments:

• The effective permeability, determined by the experiments and used for obtaining the average interstitial concentration, significantly overestimates the diffusive contribution.

